Arcus Biosciences Refocuses R&D on Casdatifan and Inflammation Programs, Plans New Clinical Trials and Data Readouts Through 2028

Reuters12-12 21:30

Arcus Biosciences Refocuses R&D on Casdatifan and Inflammation Programs, Plans New Clinical Trials and Data Readouts Through 2028

Arcus Biosciences Inc. announced a strategic shift to concentrate its research and development investment on casdatifan, a HIF-2a inhibitor, and its emerging portfolio of small molecule programs targeting inflammatory and autoimmune diseases. The company plans to expand the development program for casdatifan with studies in new early-line combinations for kidney cancer and additional tumor types, as well as to initiate a potential Phase 3 registrational study in first-line clear cell renal cell carcinoma by late 2026. Arcus also aims to advance two small molecule inhibitors-MRGPRX2, targeting atopic dermatitis and chronic spontaneous urticaria, and another yet-to-be-disclosed candidate-into clinical development in 2026. The company expects to fund its planned operations through at least the second half of 2028 with approximately $1 billion in cash and investments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251212586271) on December 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590501610?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590501610","market":"nz","top_or_hot":-1,"title":"Arcus Biosciences Refocuses R&D on Casdatifan and Inflammation Programs, Plans New Clinical Trials and Data Readouts Through 2028","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arcus Biosciences Refocuses R&amp;D on Casdatifan and Inflammation Programs, Plans New Clinical Trials and Data Readouts Through 2028\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/RCUS\">Arcus Biosciences Inc.</a> announced a strategic shift to concentrate its research and development investment on casdatifan, a HIF-2a inhibitor, and its emerging portfolio of small molecule programs targeting inflammatory and autoimmune diseases. The company plans to expand the development program for casdatifan with studies in new early-line combinations for kidney cancer and additional tumor types, as well as to initiate a potential Phase 3 registrational study in first-line clear cell renal cell carcinoma by late 2026. Arcus also aims to advance two small molecule inhibitors-MRGPRX2, targeting atopic dermatitis and chronic spontaneous urticaria, and another yet-to-be-disclosed candidate-into clinical development in 2026. The company expects to fund its planned operations through at least the second half of 2028 with approximately $1 billion in cash and investments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251212586271) on December 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arcus Biosciences Refocuses R&D on Casdatifan and Inflammation Programs, Plans New Clinical Trials and Data Readouts Through 2028</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcus Biosciences Refocuses R&D on Casdatifan and Inflammation Programs, Plans New Clinical Trials and Data Readouts Through 2028\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-12 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arcus Biosciences Refocuses R&amp;D on Casdatifan and Inflammation Programs, Plans New Clinical Trials and Data Readouts Through 2028\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/RCUS\">Arcus Biosciences Inc.</a> announced a strategic shift to concentrate its research and development investment on casdatifan, a HIF-2a inhibitor, and its emerging portfolio of small molecule programs targeting inflammatory and autoimmune diseases. The company plans to expand the development program for casdatifan with studies in new early-line combinations for kidney cancer and additional tumor types, as well as to initiate a potential Phase 3 registrational study in first-line clear cell renal cell carcinoma by late 2026. Arcus also aims to advance two small molecule inhibitors-MRGPRX2, targeting atopic dermatitis and chronic spontaneous urticaria, and another yet-to-be-disclosed candidate-into clinical development in 2026. The company expects to fund its planned operations through at least the second half of 2028 with approximately $1 billion in cash and investments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251212586271) on December 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RCUS","symbol_name":"Arcus Biosciences Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL8YzR4b:1","article_id":"2590501610","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590501610","pubTimestamp":1765546231,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Arcus Biosciences Refocuses R&D on Casdatifan and Inflammation Programs, Plans New Clinical Trials and Data Readouts Through 2028. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire  on December 12, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RCUS":"Arcus Biosciences Inc.","BK4139":"生物科技"},"translate_title":"Arcus Biosciences将研发重点重新放在Casdatifan和炎症项目上，计划到2028年进行新的临床试验和数据读数","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RCUS":0.9},"content_text":"Arcus Biosciences Refocuses R&D on Casdatifan and Inflammation Programs, Plans New Clinical Trials and Data Readouts Through 2028\n    \n\nArcus Biosciences Inc. announced a strategic shift to concentrate its research and development investment on casdatifan, a HIF-2a inhibitor, and its emerging portfolio of small molecule programs targeting inflammatory and autoimmune diseases. The company plans to expand the development program for casdatifan with studies in new early-line combinations for kidney cancer and additional tumor types, as well as to initiate a potential Phase 3 registrational study in first-line clear cell renal cell carcinoma by late 2026. Arcus also aims to advance two small molecule inhibitors-MRGPRX2, targeting atopic dermatitis and chronic spontaneous urticaria, and another yet-to-be-disclosed candidate-into clinical development in 2026. The company expects to fund its planned operations through at least the second half of 2028 with approximately $1 billion in cash and investments.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251212586271) on December 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590501610","isCrawlerRequest":true}